Condition: Large HCC Patients · Stereotactic Body Radiation Therapy · Transcatheter Arterial Chemoembolization · Sponsor: Beijing 302 Hospital
The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.
This description comes directly from the study's public registry record.
Jing Sun · +8613718681094 · 519299998@qq.com
Xuezhang Duan · +8613621386161 · duanxuezhang2006@163.com
Always discuss trial participation with your own doctor first.
| Beijing 302 hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04512846